Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib induction study in moderate to severe ulcerative colitis
MOH_2019-01-24_004863Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of upadacitinib in autoimmune colitis (3 arms), sponsored by AbbVie Inc. Started Dec 2018; status: completed.
02
Drugs
upadacitinib
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2019-01-24_004863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-01-24_004863.